Biosimilars; A unique opportunity for Iran national health sector and national pharmaceutical industry

DARU, Journal of Pharmaceutical Sciences

Volumn 20, Issue 1, 2012, Pages

  Cheraghali, Abdol Majid ^a  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Biopharmaceuticals; Biosimilars; Iran

Indexed keywords

BIOSIMILAR AGENT; GENERIC DRUG;

BIOEQUIVALENCE; CLINICAL TRIAL (TOPIC); COST CONTROL; DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MARKETING; DRUG SCREENING; IRAN; PRACTICE GUIDELINE; REVIEW;

EID: 84870226749     PISSN: 15608115     EISSN: 20082231     Source Type: Journal    
DOI: 10.1186/2008-2231-20-35     Document Type: Review

References (20)

1. Addressing the health technology assessment of biosimilar pharmaceuticals. Stewart A, Aubrey P, Belsey J, Curr Med Res Opin 2010 26 2119 2126 10.1185/03007995.2010.505137 20649394
2. Biosimilars-the way forward. Zuniga L, Calve B, Hosp Pharm Europe 2010 50 33 34
3. Generics and Biosimilars Initiative. GaBI Online, Current status of biosimilar development Available from: http://www.gabionline.net/Biosimilars/ General/Current-status-of-biosimilar-development
4. Quantitative evaluation of bioequivalence/biosimilarity. Chow SC, J Bioequiv Availab 2011 Available from: http://www.gabionline.net/Biosimilars/ Research/Quantitative-evaluation-of-bioequivalence
5. Biosimilars: controversies as illustrated by rhGH. Declerck PJ, Darendeliler F, Gáth M, Kolouskova S, Micle I, Noordam C, et al. Curr Med Res Opin 2010 26 1219 29 10.1185/03007991003719642 20302553
6. Annex guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. European Medicines Agency, Guidance on similar medicinal products containing somatropin 2006 Available from: http://www.ema.europa.eu/pdfs/human/ biosimilar/9452805en.pdf
7. WHO/KFDA joint workshop on implementing WHO guidelines on evaluating similar biotherapeutic products, Seoul, Republic of Korea 24-26 August, 2010. Wadhwa M, Kang HN, Knezevic I, Thorpe R, Griffiths E, Biologicals 2011 39 349 357 10.1016/j.biologicals.2011.08.009 21906959
8. World Health Organization, Guidelines on evaluation of similar biotherapeutic products (SBPs) 2010 http://www.who.int/biologicals/areas/ biological-therapeutics/BIOTHERAPEUTICS-FOR-WEB-22APRIL2010.pdf
9. Clinical comparability and European biosimilar regulations. Schellekens H, Moors E, Nat Biotechnol 2010 28 28 31 10.1038/nbt0110-28 20062035
10. Worldwide experience with biosimilar development. McCamish M, Woollert G, MAbs 2011 3 209 17 10.4161/mabs.3.2.15005 21441787
11. Biosimilar epoetins: how similar are they? Schellekens H, Eur J Hosp Pharm 2004 10 243 7
12. Binocrit: assemssment of quality, safety and efficacy of biopharmaceuticals. Brockmeyer C, Seidl A, Eur J Hosp Pharm Prac 2009 15 34 40
13. Biosimilar medicines and cost-effectiveness. Simoens S, Clinicoecon Outcomes Res 2011 3 29 36 21935330
14. The EGAs thoughts on how to improve the legal and regulatory framework for generic and biosimilar medicines. European Generic Medicines Association, Vision 2015 2010 Available from: http://www.egagenerics.com/doc/EGA-Vision-2015. pdf
15. Generics and biosimilars initiative. GaBI Online, Sandoz announces biosimilar Available from: http://www.gabionline.net/Biosimilars/News/Sandoz- announces-biosimilar-rituximab
16. Generics and biosimilars initiative. GaBI Online, Biosimilars boost for South Korea Available from: http://www.gabionline.net/Biosimilars/News/ Biosimilars-boost-for-South-Korea
17. Current regulatory and scientific considerations for approving biosimilars in Iran. Hadavand N, Valadkhani M, Zarbakhsh A, Biologicals 2011 39 325 327 10.1016/j.biologicals.2011.06.019 21873077
18. Iran Pharmaceutical Market. Cheraghali AM, Iran J Pharm Research 2006 5 1 7
19. New national drug policy in Iran leading to expanded pharmaceutical market and extended access of public to medicines. Dinarvand R, Iran J Publ Health 2009 38 S1 158 161
20. Pharmaceutical market and health system in the Middle Eastern and Central Asian countries: Time for innovations and changes in policies and actions. Abdollahiasl A, Nikfar S, Abdollahi M, Arch Med Sci 2011 3 365 367